American Association for Cancer Research
15357163mct190022-sup-214978_2_supp_5726164_pwlpwl.docx (67.24 kB)

Supplemental Figure S2 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer

Download (67.24 kB)
journal contribution
posted on 2023-04-03, 15:21 authored by Kerry A. Whalen, Brian H. White, James M. Quinn, Kristina Kriksciukaite, Rossitza Alargova, Tsun P. Au Yeung, Patrick Bazinet, Adam Brockman, Michelle M. DuPont, Haley Oller, James Gifford, Charles-Andre Lemelin, Patrick Lim Soo, Samantha Perino, Benoît Moreau, Gitanjali Sharma, Rajesh Shinde, Beata Sweryda-Krawiec, Mark T. Bilodeau, Richard Wooster

In vitro inhibition of proliferation of SCLC cells by PEN-221 or DM1



Small cell lung cancer (SCLC) is an aggressive neuroendocrine carcinoma with a 95% mortality rate with no improvement to treatment in decades, and new therapies are desperately needed. PEN-221 is a miniaturized peptide–drug conjugate (∼2 kDa) designed to target SCLC via a Somatostatin Receptor 2 (SSTR2)–targeting ligand and to overcome the high proliferation rate characteristic of this disease by using the potent cytotoxic payload, DM1. SSTR2 is an ideal target for a drug conjugate, as it is overexpressed in SCLC with limited normal tissue expression. In vitro, PEN-221 treatment of SSTR2-positive cells resulted in PEN-221 internalization and receptor-dependent inhibition of cellular proliferation. In vivo, PEN-221 exhibited rapid accumulation in SSTR2-positive SCLC xenograft tumors with quick clearance from plasma. Tumor accumulation was sustained, resulting in durable pharmacodynamic changes throughout the tumor, as evidenced by increases in the mitotic marker of G2–M arrest, phosphohistone H3, and increases in the apoptotic marker, cleaved caspase-3. PEN-221 treatment resulted in significant antitumor activity, including complete regressions in SSTR2-positive SCLC xenograft mouse models. Treatment was effective using a variety of dosing schedules and at doses below the MTD, suggesting flexibility of dosing schedule and potential for a large therapeutic window in the clinic. The unique attributes of the miniaturized drug conjugate allowed for deep tumor penetration and limited plasma exposure that may enable long-term dosing, resulting in durable tumor control. Collectively, these data suggest potential for antitumor activity of PEN-221 in patients with SSTR2-positive SCLC.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager